Navigation Links
Actavis and Warner Chilcott Announce Effectiveness of Registration Statement on Form S-4
Date:7/31/2013

ency approvals or actions, if any; costs and efforts to defend or enforce intellectual property rights; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with governmental regulations applicable to Actavis' and Warner Chilcott's manufacturers, facilities, products and/or businesses; changes in the laws and regulations affecting, among other things, pricing and reimbursement of pharmaceutical products; changes in tax laws or interpretations that could increase Actavis' consolidated tax liabilities; the loss of key senior management or scientific staff; and such other risks and uncertainties detailed in Actavis' periodic public filings with the SEC including but not limited to Actavis' Quarterly Report on Form 10-Q for the quarters ended March 31, 2013 and June 30, 2013 and Actavis' Annual Report on Form 10-K for the year ended December 31, 2012 (as revised pursuant to Actavis' Current Report on Form 8-K dated as of June 17, 2013, which was filed with the SEC on June 18, 2013), as well as the Form S-4.  Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements.

Warner Chilcott Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements, including statements concerning the proposed transaction with Actavis, Warner Chilcott's industry, Warner Chilcott's operations, Warner Chilcott's anticipated financial performance and financial condition and Warner Chilcott's business plans, growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions ar
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
10. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
11. Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... PLEASANTON, Calif. , April 28, 2015  Clinicians ... Boise, Idaho , will demonstrate that Leaf Healthcare,s ... with a caregiver,s pressure ulcer prevention turn protocols. Their ... Wound Care in San Antonio, Texas ... will present a poster entitled "Optimizing patient turning resources ...
(Date:4/28/2015)... April 28, 2015 Exagen Diagnostics, Inc., ... significant unmet need for the accurate diagnosis and ... announced today that its Avise SLE+ Connective Tissue ... orders since launch, and that adoption continues to ... identifying Connective Tissue Disease (CTD), including, but not ...
(Date:4/28/2015)... 2015 New and more complex medicines ... of manufacturers, payers, pharmacists and patients. Now ... premiere journal, is partnering with the National Association ... association dedicated solely to this developing field, to ... this growing need. "This partnership provides ...
Breaking Medicine Technology:VA Presentation at Wound Symposium to Show New Wireless Patient Monitoring System Improves Pressure Ulcer Turn Compliance 2VA Presentation at Wound Symposium to Show New Wireless Patient Monitoring System Improves Pressure Ulcer Turn Compliance 3VA Presentation at Wound Symposium to Show New Wireless Patient Monitoring System Improves Pressure Ulcer Turn Compliance 4Exagen Sees Growing Adoption of Avise Diagnostic for Connective Tissue Disease with New Milestone 2Specialty Pharmacy Times Partners With National Association of Specialty Pharmacy to Improve Care for Patients 2Specialty Pharmacy Times Partners With National Association of Specialty Pharmacy to Improve Care for Patients 3Specialty Pharmacy Times Partners With National Association of Specialty Pharmacy to Improve Care for Patients 4
... The nationwide launch of the Recovery Audit Contractor (RAC) program ... sizes and types are busy preparing for it as not ... findings resulting in money owed to Medicare. Think adding staff ... with mountains of new work. Designed based on the experiences ...
... Bionovo Inc. (Nasdaq: BNVI ) announced today the ... effect of tamoxifen on estrogen receptor beta (ERb) gene ... published in Molecular and Cellular Endocrinology, demonstrate that tamoxifen ... of breast cancer cell proliferation. , "Tamoxifen has ...
Cached Medicine Technology:American Hospital Association (AHA) Names OnBase 'RACTrac Compatible' 2American Hospital Association (AHA) Names OnBase 'RACTrac Compatible' 3Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta 2Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta 3
(Date:4/28/2015)... PA (PRWEB) April 28, 2015 Helping ... decision-making process when a loved one dies can be ... the funeral arrangements and final tribute can ... families in need, Beinhauer Family Funeral Homes ... services offered to families by doubling its number of ...
(Date:4/28/2015)... 28, 2015 Two leaders in patient ... to Becker's Hospital Review’s list of 50 Experts ... Pronovost, M.D., Ph.D. , director of the Armstrong ... vice president for patient safety and quality at Johns ... vice president of medical affairs and chief patient safety ...
(Date:4/28/2015)... Georgia State University’s School of Public ... will partner with the school on efforts to improve ... that produces more tobacco and has more smokers than ... Tobacco Control Partnership-Tobacco Free Cities, will focus on a ... support tobacco control efforts and where public health organizations ...
(Date:4/28/2015)... 2015 Vancouver personal injury lawyers at ... it is smarter to call an attorney before calling ... The blog reasons that there are several benefits of ... well-versed with the law and can help clients reach ... to on their own. Competent and experienced personal injury ...
(Date:4/28/2015)... 28, 2015 The biologics safety testing ... drivers for the market include growth of the pharmaceutical ... drug launches. Over the years, the number of drug ... and 2010, the FDA approved 225 drug applications and ... Europe accounted for 3,822 of the pharmaceutical and 1,998 ...
Breaking Medicine News(10 mins):Health News:Beinhauer's Increasing Number of Celebrants to Meet Growing Demand for Personalized Funeral Ceremonies 2Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 2Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 3Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 4Health News:Georgia State Names Partner Cities For Tobacco Control Project 2Health News:Vancouver Personal Injury Lawyers Recently Stated in Latest Blog That It Is Smarter To Call A Lawyer Before ICBC 2Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 2Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 3Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 4
... STAMFORD, Conn., Aug. 27 American children miss more ... other two diseases combined.(1) As parents help their kids prepare for ... a lifetime of good oral health with the new Philips Sonicare ... Sonicare For Kids is specially designed to support kids, needs at ...
... , DES PLAINES, Ill. and NEW ... into an agreement with Pfizer Inc to develop a molecular diagnostic ... the presence of gene rearrangements. Pfizer has developed a novel ... of many cancers. To be eligible to receive Pfizer,s oral ...
... those with deceased donor transplant organs, study shows , ... disease may do just as well receiving treatment at ... donor, new research has found. , Researchers in Canada ... had either received a kidney transplant from a deceased ...
... , , , ... and CHATTANOOGA, Tenn., Aug. 27 Sandata Technologies, Inc., a ... healthcare and social services communities, and Volunteer State Health Plan ... announced an agreement by which VSHP will use Sandata,s IntegriCare ...
... China, Aug. 27 /PRNewswire-Asia/ -- On August 10, 2009, Winner,Medical ... entered into a contract with a machine producer in China ... This new machineries will constitute the ... operated in the Company,s,subsidiary in Huanggang, and it is expected ...
... , , CUPERTINO, Calif., ... today reported that it has signed an exclusive long term ... Inc. (NYSE: KG ). This agreement stipulates the ... based on DURECT,s manufacturing cost plus a specified percentage mark-up, ...
Cached Medicine News:Health News:Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush 2Health News:Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush 3Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 2Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 3Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 4Health News:Home Dialysis a Good Option for Kidney Disease Patients 2Health News:Sandata Selected by Volunteer State Health Plan to Manage TennCare Choices 2Health News:Winner Medical Purchased New Purcotton Production Line to Meet Increasing Demand 2Health News:Winner Medical Purchased New Purcotton Production Line to Meet Increasing Demand 3Health News:DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R) 2Health News:DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R) 3Health News:DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R) 4
... Stylish and comfortable eye protection Properly ... 90% of scatter radiation. Our high quality ... and comfort with minimized weight. Our lenses ... optics that meet all industry standards. Most ...
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
... lenses and frames are designed with the safety ... lenses are Schott RS-520 (also called SF-6) leaded ... These lenses meet standards, as set for optical ... ,While our eyewear is protecting your eyes, ...
... and frames are designed with the safety and ... are Schott RS-520 (also called SF-6) leaded glass, ... lenses meet standards, as set for optical clarity, ... ,While our eyewear is protecting your eyes, it ...
Medicine Products: